📞 +91-7667918914 | ✉️ iarjset@gmail.com
International Advanced Research Journal in Science, Engineering and Technology
International Advanced Research Journal in Science, Engineering and Technology A Monthly Peer-Reviewed Multidisciplinary Journal
ISSN Online 2393-8021ISSN Print 2394-1588Since 2014
IARJSET aligns to the suggestive parameters by the latest University Grants Commission (UGC) for peer-reviewed journals, committed to promoting research excellence, ethical publishing practices, and a global scholarly impact.
← Back to VOLUME 8, ISSUE 4, APRIL 2021

Machine Learning Approaches for Signaling Adverse Drug Reaction with Covid-19 RNA Vaccines

Pramila Roselin A, Anitha K L

👁 1 view📥 0 downloads
Share: 𝕏 f in

Abstract: Coronavirus disease 2019 (COVID-19) is currently resulted as a worldwide pandemic. It is caused by SARS-CoV-2. A COVID-19 vaccine is intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS CoV 2). The objective of this paper is to define the severity and the intensity of adverse reaction for Covid-19 mRNA vaccines. Based on the dataset collected, how many of them got mild reactions, moderate and severe for each mRNA vaccine. 92.30% of them face severe symptoms after using Pfizer-BioNTech vaccine. 100% chance of people experience severe symptoms after using Moderna vaccine. There are slight changes in number of them face severe symptoms from these two mRNA vaccines. By using multi-class classification, found that comparatively Moderna give more adverse reactions than Pfizer-BioNTech.

Keywords: Machine Learning, Covid-19, Adverse Drug Reaction, Pfizer-BioNTech vaccine, Moderna Vaccine, Multi-class Classification.

How to Cite:

[1] Pramila Roselin A, Anitha K L, “Machine Learning Approaches for Signaling Adverse Drug Reaction with Covid-19 RNA Vaccines,” International Advanced Research Journal in Science, Engineering and Technology (IARJSET), DOI: 10.17148/IARJSET.2021.8403

Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 International License.